BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34018212)

  • 21. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
    Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.
    Liau JY; Tsai JH; Yuan RH; Chang CN; Lee HJ; Jeng YM
    Mod Pathol; 2014 Aug; 27(8):1163-73. PubMed ID: 24406866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
    Komuta M
    Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
    D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
    J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
    Wang AQ; Zheng YC; Du J; Zhu CP; Huang HC; Wang SS; Wu LC; Wan XS; Zhang HH; Miao RY; Sang XT; Zhao HT
    World J Gastroenterol; 2016 May; 22(18):4459-65. PubMed ID: 27182157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
    Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
    HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma.
    Balitzer D; Joseph NM; Ferrell L; Shafizadeh N; Jain D; Zhang X; Yeh M; di Tommaso L; Kakar S
    Mod Pathol; 2019 Oct; 32(10):1486-1494. PubMed ID: 31186529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
    Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
    Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
    Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y
    Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
    Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
    Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
    Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
    Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
    Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
    Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.
    Itoyama M; Hata M; Yamanegi K; Yamada N; Ohyama H; Hirano H; Terada N; Nakasho K
    Med Mol Morphol; 2012 Dec; 45(1):7-13. PubMed ID: 22431178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH
    Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ubiquitin-specific protease 14 expression associated with intrahepatic cholangiocarcinoma cell differentiation.
    Chuensumran U; Saelee P; Punyarit P; Wongkham S; Pairojkul C; Chauin S; Petmitr S
    Asian Pac J Cancer Prev; 2011; 12(3):775-9. PubMed ID: 21627382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin.
    Asayama Y; Taguchi Ki K; Aishima Si S; Nishi H; Masuda K; Tsuneyoshi M
    Liver; 2002 Feb; 22(1):43-50. PubMed ID: 11906618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
    Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
    Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.
    Goeppert B; Toth R; Singer S; Albrecht T; Lipka DB; Lutsik P; Brocks D; Baehr M; Muecke O; Assenov Y; Gu L; Endris V; Stenzinger A; Mehrabi A; Schirmacher P; Plass C; Weichenhan D; Roessler S
    Hepatology; 2019 May; 69(5):2091-2106. PubMed ID: 30615206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality.
    Na HY; Kim JH; Kim H; Cho JY; Han HS; Jang ES; Kim JW; Jeong SH; Heo J; Kim JW; Kim JW; Ahn S
    Histopathology; 2024 Jan; 84(2):402-408. PubMed ID: 37903726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.